Clinical Trials Search

Department: Gastroenterology
Diagnosis: Gastrointestinal - Ulcerative Colitis
Principal Investigator: Georgetson MD, FACG, Michael
Sponsor: AbbVie
Details (Identifier #): NCT02819635
Title: AbbVie M14-234, A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of ABT-494 for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis
Department: Gastroenterology
Diagnosis: Gastrointestinal - Ulcerative Colitis
Principal Investigator: Georgetson MD, FACG, Michael
Sponsor: AbbVie
Details (Identifier #): NCT03006068
Title: M14-533, A Phase 3 Multicenter, Open-Label Extension (OLE) Study to Evaluate the Long-Term Safety and Efficacy of ABT-494 in Subjects with Ulcerative Colitis (UC)
Department: Oncology
Diagnosis: Gastrointestinal - Liver
Principal Investigator:
Sub-Investigator(s):
Sponsor: Internal
Details (Identifier #): none
Title: A Humanitarian Device Exemption Use Protocol of TheraSphere For Treatment of Unresectable Primary or Secondary Liver Neoplasia
Department: Oncology
Diagnosis: Lung- Non-Small Cell
Principal Investigator: Lowry MD, Philip
Sponsor: BMS
Details (Identifier #): NCT02477826
Title: BMS CA209227: An Open-Label, Randomized Phase 3 Trial of Nivolumab, or Nivolumab plus Ipilimumab, or Nivolumab plus platinum doublet chemotherapy versus platinum doublet chemotherapy in Subjects with Chemotherapy-Naïve Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)
Department: Oncology
Diagnosis: Lung- Small Cell
Principal Investigator: Lowry MD, Philip
Sponsor: BMS
Details (Identifier #): NCT02538666
Title: BMS CA209-451-0002, A Randomized, Multicenter, Double-Blind, Phase 3 Study of Nivolumab, Nivolumab in Combination with Ipilimumab, or Placebo as Maintenance Therapy in Subjects with Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) after Completion of Platinum-based First Line Chemotherapy